| Triple-negative breast cancer (82% of patients): |
- If treated with adjuvant chemotherapy, were required to have axillary node-positive disease or an invasive primary tumor measuring at least 2 cm on pathologic analysis.
|
- If treated with neoadjuvant chemotherapy, were required to have residual invasive breast cancer in the breast or resected lymph nodes (ie, no pCR from neoadjuvant therapy).
|
| Hormone receptor-positive breast cancer (18% of patients): |
- If treated with adjuvant chemotherapy, were required to have at least 4 pathologically confirmed positive lymph nodes.
|
- If treated with neoadjuvant chemotherapy, were required to have not had a pCR with a CPS+EG score of 3 or higher.[2,3] The CPS+EG scoring system estimates relapse probability on the basis of clinical and pathologic stage (CPS) and estrogen receptor status and histologic grade (EG); scores range from 0 to 6, with higher scores indicating worse prognosis.
|
